Isidoro Aranda-Barneto
Cordoba, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.
Journal: ESMO open
Published: August 04, 2025
Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Journal: Cancer medicine
Published: February 27, 2025
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: September 26, 2024
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Journal: Journal for immunotherapy of cancer
Published: September 13, 2022
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 16, 2022
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
Journal: Journal for immunotherapy of cancer
Published: July 29, 2021
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Journal: Clinical and translational medicine
Published: April 13, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 31, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 17, 2021
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: May 14, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026